• LAST PRICE
    5.1700
  • TODAY'S CHANGE (%)
    Trending Down-0.2400 (-4.4362%)
  • Bid / Lots
    5.0900/ 2
  • Ask / Lots
    5.2300/ 1
  • Open / Previous Close
    5.4000 / 5.4100
  • Day Range
    Low 5.0750
    High 5.5098
  • 52 Week Range
    Low 2.5700
    High 7.0000
  • Volume
    991,715
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • May 9, 2024

      Show headlines and story abstract
    • 7:30AM ET on Thursday May 09, 2024 by GlobeNewswire
      Companies Mentioned: CRMD
    • 7:30AM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: CRMD
      Short-term investments $ 23,370,989 $ 32,388,130 Total Assets $ 68,023,742 $ 82,059,957 Total Liabilities $ 10,011,022 $ 11,917,528 Accumulated deficit $(336,166,136) $(321,700,013) Total Stockholders' Equity $ 58,012,720 $ 70,142,429 CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Three Months Ended March 31, -------------------------------- 2024 2023 Cash Flows from Operating Activities: Net loss $ (14,466,123) $ (10,567,226) Net cash used in operating activities (17,310,294) (10,393,886) Cash Flows Used in Investing Activities: Net cash provided by (used in) investing activities 8,944,932 (14,686,805) Cash Flows from Financing Activities: Net cash (used in) provided by financing activities (97,118) 7,200,406 Net Decrease in Cash and Cash Equivalents (8,463,285) (17,878,001) Cash and Cash Equivalents and Restricted Cash - Beginning of Period 43,823,192 43,374,745 Cash and Cash Equivalents and Restricted Cash - End of Period $ 35,359,907 $ 25,496,744
    • 7:30AM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: CRMD
      Short-term investments $ 23,370,989 $ 32,388,130 Total Assets $ 68,023,742 $ 82,059,957 Total Liabilities $ 10,011,022 $ 11,917,528 Accumulated deficit $(336,166,136) $(321,700,013) Total Stockholders' Equity $ 58,012,720 $ 70,142,429 CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Three Months Ended March 31, -------------------------------- 2024 2023 Cash Flows from Operating Activities: Net loss $ (14,466,123) $ (10,567,226) Net cash used in operating activities (17,310,294) (10,393,886) Cash Flows Used in Investing Activities: Net cash provided by (used in) investing activities 8,944,932 (14,686,805) Cash Flows from Financing Activities: Net cash (used in) provided by financing activities (97,118) 7,200,406 Net Decrease in Cash and Cash Equivalents (8,463,285) (17,878,001) Cash and Cash Equivalents and Restricted Cash - Beginning of Period 43,823,192 43,374,745 Cash and Cash Equivalents and Restricted Cash - End of Period $ 35,359,907 $ 25,496,744

Peers Headlines